SLIDE 3 3/16/2020 3
NCDHHS, Division of Public Health | Women’s Health Agreement Addenda Webinar, Fiscal Year 2020-2021 | March 17, 2020 7
- III. Scope of Work and Deliverables
- C. Policies and Procedures Section
C18 Develop and follow a policy/procedure/protocol for assessing prenatal clients for immunity to
Rubella and Varicella, and for provision of or referral for the Rubella and Varicella vaccine postpartum if the patient is not immune. Rubella and Varicella immunity status must be assessed at the initial prenatal appointment. Patients who have written official documentation of vaccination with 1 dose of live rubella, MMR, or MMRV vaccine at age 1 year or older, or who have laboratory evidence of immunity are considered to be immune to Rubella. Patients who have written official documentation of vaccination with 2 doses of varicella vaccine, initiated at age 1 year or older and separated by at least one month; laboratory evidence of immunity or laboratory confirmation of disease, or history of healthcare provider diagnosis of varicella or herpes zoster disease are considered to be immune to varicella. (ACOG Committee Opinion, No. 741, June 2018; Guidelines for Perinatal Care, 8th ed., pp. 134-135, 166; CDC Pink Book, Chapter 20 & 22) Patients who are not immune to rubella and/or varicella must be referred for or provided appropriate vaccination during the postpartum period. (ACOG Committee Opinion,
- No. 741, June 2018; Guidelines for Perinatal Care, 8th ed., pp. 164-166, 283, 519-524)
CLARIFICATION: Items (E8 & E9) from Laboratory and Other Studies were moved to Policies and Procedures (C18) to clarify the specific details that need to be in the policy regarding assessment of Rubella and Varicella immunity.
NCDHHS, Division of Public Health | Women’s Health Agreement Addenda Webinar, Fiscal Year 2020-2021 | March 17, 2020 8
- III. Scope of Work and Deliverables
- C. Policies and Procedures Section
C19 Develop and follow a policy/procedure/protocol that describes the agency’s use of 17
α Hydroxyprogesterone Caproate (17P) for patients at risk for developing preterm labor as defined by a history of a prior spontaneous birth at less than 37 weeks gestation. Patients eligible for this therapy include:
- a. History of previous singleton spontaneous preterm birth between 20 weeks 0 days and 36 weeks 6
days gestation.
- b. Have a current singleton pregnancy.
Guidelines for initiation of 17P:
- c. Initiate treatment between 16 weeks 0 days and 21 weeks 6 days gestation.
- d. If an eligible patient presents to prenatal care late, this therapy may be initiated as late as 23
weeks 6 days.
CLARIFICATION: Item (F1) from Medical Therapy section was moved to Policies and Procedures (C19) to ensure LHDs specifically state patient eligibility criteria for 17P in the policy, procedure or protocol.
NCDHHS, Division of Public Health | Women’s Health Agreement Addenda Webinar, Fiscal Year 2020-2021 | March 17, 2020 9
- III. Scope of Work and Deliverables
- C. Policies and Procedures Section
C21 Develop and follow policy/procedure/protocol for completing the following validated screening tools: (1) PHQ-9 at the initial prenatal visit and as indicated by patient’s responses to the Maternal Health History Forms C-1 (4158 on WHB website) & C-2 (4160 on WHB website) in the 2nd or 3rd trimester and (2) PHQ-9 or Edinburgh Postnatal Depression Scale (EPDS) at postpartum visit. Policy should include referral and follow-up processes, if indicated by the screening tools. CLARIFICATION: Clarified which forms are to be used in the 2nd and 3rd trimester, if additional screening is indicated.
7 8 9